Wängberg B, Nilsson O, Wigander A, Johansson V, Forssell-Aronsson E, Andersson P, Fjälling M, Tisell L E, Ahlman H
Avdelningen för kirurgi, Sahlgrenska sjukhuset, Göteborg.
Lakartidningen. 1997 Mar 5;94(10):829-30, 835-8.
Verification of the presence of somatostatin receptors on neuroendocrine tumour cells opened up unique diagnostic and therapeutic possibilities. Long-acting somatostatin analogues are currently used to alleviate symptoms of excessive hormone synthesis in patients with such tumours. Radiolabelled somatostatin analogues can be used both for high specificity and high sensitivity scintigraphic localisation of such tumours and for intraoperative scintillation detection. Detailed studies in patients and in tumour cells in vitro have shown 111In-octreotide uptake to be high and retention times long in tumour tissue, and have yielded evidence of intracellular localisation of the radionuclide. These findings thus showed somatostatin receptor-mediated radiotherapy to be a possible treatment alternative after close characterisation of the individual tumour. In the future, it may be possible to use other peptide receptors (e g, growth factor receptors) according to the same principles as applied in the case of somatostatin receptors.
对神经内分泌肿瘤细胞上生长抑素受体存在情况的验证开启了独特的诊断和治疗可能性。长效生长抑素类似物目前用于缓解此类肿瘤患者激素过度合成的症状。放射性标记的生长抑素类似物可用于此类肿瘤的高特异性和高灵敏度闪烁显像定位以及术中闪烁检测。对患者和体外肿瘤细胞的详细研究表明，111铟-奥曲肽在肿瘤组织中的摄取量高且保留时间长，并有证据表明放射性核素在细胞内定位。这些发现因此表明，在对个体肿瘤进行仔细特征描述后，生长抑素受体介导的放射治疗可能是一种治疗选择。未来，根据应用于生长抑素受体的相同原理，有可能使用其他肽受体（如生长因子受体）。
